23.88
price down icon2.81%   -0.69
after-market  After Hours:  23.88 
loading
Smith & Nephew plc ADR stock is currently priced at $23.88, with a 24-hour trading volume of 1.17M. It has seen a -2.81% decreased in the last 24 hours and a -7.59% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $24.54 pivot point. If it approaches the $24.25 support level, significant changes may occur.
Previous Close:
$24.57
Open:
$24.36
24h Volume:
1.17M
Market Cap:
$10.44B
Revenue:
$5.55B
Net Income/Loss:
$263.00M
P/E Ratio:
47.76
EPS:
0.5
Net Cash Flow:
-
1W Performance:
-0.54%
1M Performance:
-7.59%
6M Performance:
+8.99%
1Y Performance:
-24.21%
1D Range:
Value
$23.86
$24.38
52W Range:
Value
$21.52
$33.09

Smith & Nephew plc ADR Stock (SNN) Company Profile

Name
Name
Smith & Nephew plc ADR
Name
Phone
44 20 7401 7646
Name
Address
15 Adam Street, London
Name
Employee
15,000
Name
Twitter
@smithnephewplc
Name
Next Earnings Date
Name
Latest SEC Filings
Name
SNN's Discussions on Twitter

Smith & Nephew plc ADR Stock (SNN) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-28-23 Upgrade Barclays Underweight → Equal Weight
Nov-03-23 Upgrade JP Morgan Neutral → Overweight
Oct-31-23 Upgrade HSBC Securities Hold → Buy
Oct-13-23 Initiated Stifel Hold
Aug-08-23 Upgrade UBS Sell → Neutral
Apr-27-23 Downgrade HSBC Securities Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-12-22 Initiated Citigroup Buy
Nov-28-22 Downgrade UBS Neutral → Sell
Oct-18-22 Initiated Morgan Stanley Equal-Weight
Jul-28-22 Downgrade Canaccord Genuity Buy → Hold
Mar-16-22 Initiated RBC Capital Mkts Outperform
Mar-15-22 Initiated RBC Capital Mkts Outperform
Mar-04-22 Upgrade Redburn Sell → Neutral
Jun-09-21 Upgrade Credit Suisse Neutral → Outperform
Dec-18-20 Upgrade Bernstein Mkt Perform → Outperform
Dec-01-20 Initiated Barclays Overweight
Jul-29-20 Upgrade BofA Securities Neutral → Buy
Jun-04-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-14-20 Downgrade Citigroup Buy → Neutral
Nov-21-19 Initiated Citigroup Buy
Nov-12-19 Initiated Bernstein Outperform
Jul-23-19 Upgrade Berenberg Hold → Buy
Feb-08-19 Downgrade Exane BNP Paribas Outperform → Neutral
Jan-02-19 Downgrade JP Morgan Overweight → Neutral
Dec-10-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-01-18 Reiterated Canaccord Genuity Buy
Jan-25-18 Upgrade JP Morgan Neutral → Overweight
Dec-11-17 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-11-17 Initiated Canaccord Genuity Buy
Feb-27-17 Downgrade Goldman Buy → Neutral
Jan-19-17 Initiated HSBC Securities Hold
Dec-08-16 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-06-16 Downgrade Berenberg Buy → Hold
Feb-26-16 Initiated Cantor Fitzgerald Hold
View All

Smith & Nephew plc ADR Stock (SNN) Financials Data

Smith & Nephew plc ADR (SNN) Revenue 2024

SNN reported a revenue (TTM) of $5.55 billion for the quarter ending December 31, 2023, a +6.47% rise year-over-year.
loading

Smith & Nephew plc ADR (SNN) Net Income 2024

SNN net income (TTM) was $263.00 million for the quarter ending December 31, 2023, a -49.81% decrease year-over-year.
loading

Smith & Nephew plc ADR (SNN) Earnings per Share 2024

SNN earnings per share (TTM) was $0.602 for the quarter ending December 31, 2023, a -49.46% decline year-over-year.
loading
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
medical_devices PHG
$20.72
price down icon 1.19%
medical_devices STE
$201.54
price down icon 0.62%
$310.50
price down icon 1.05%
medical_devices ZBH
$119.75
price down icon 1.17%
medical_devices EW
$88.01
price down icon 0.68%
$138.01
price up icon 0.10%
Cap:     |  Volume (24h):